Drug · Small Molecule

Cabozantinib

CI-DRUG-00000131Explore in graph →NCIt C52200 CHEMBL2105717 CIViC Approved

Regulatory

Approvals (20)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory20 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CABOMETYX (DIN 02480824) under ATC L01EX07 CABOZANTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 10, 2018	health-canada-dpd
CA

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	104	50	28	239	20	CA, EU, US	Nov 29, 2012	2005-09
Malignant Kidney Neoplasm	Approved	Phase 4	42	20	13	65	3	EU, US	Apr 25, 2016	2010-04
Malignant Liver Neoplasm	Approved	Phase 3	15	8	3	30	1	US	Apr 25, 2016	Oct 30, 2012
Malignant Thyroid Gland Neoplasm	Approved	Phase 4	7	2	4	17

Curated evidence

Clinical evidence (19)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–19 of 19 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MET Amplification1
Cabozantinib	Gastric Adenocarcinoma

Clinical trials

Trials with this intervention (246)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 246 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04071223	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study	active not recruiting	Phase 2	98	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT05136196	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Molecule

Record

Kind: Small Molecule
Mechanism: Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
Targets: 2 genes
UNII: DR7ST46X58
Aliases: 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-, BMS-907351, BMS-907351 FREE BASE, CABOMETYX, Cabozantinib, CABOZANTINIB (BMS-907351), CABOZANTINIBCT-XL184COMETRIQXL184C3627, Cabozantinib Malate, CABOZANTINIB S-MALATE, COMETRIQ, N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide, XL 184, XL184, XL184,BMS-907351, XL-184 FREE BASE, XL184 FREE BASE

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (10)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01EX07	CABOZANTINIB
ATC (WHO)	L01XE

MET Fusion1

Cabozantinib

Infantile FibrosarcomaALIAS

Predictive

Supports Sensitivity Response

submitted

EID8892

We describe a novel RBPMS-MET driver fusion in association with a locally aggressive IFS-like tumor. MET functions as an oncogene and, when associated with the RNA binding protein RBPMS, forms an in-f… (full text at CIViC)

PMID 33028644 · Gupta et al., 2020 · Open in CIViC

MET Exon 14 Skipping Mutation2
Cabozantinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11400 A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC	civic
Cabozantinib + CrizotinibSequential	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11410 A 77-year old woman was diagnosed with lung adenocarcinoma harboring a MET exon 14 skipping mutation after PET-CT scans showed a right upper lobe mass, right hilar enlarged lymph nodes, and multiple b… (full text at CIViC) PMID 33530219 · Qin et al., 2021 · Open in CIViC	civic

ROS1 Fusion + ROS1 G2032R2
Cabozantinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1101 Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival o… (full text at CIViC) PMID 25351743 · Katayama et al., 2015 · Open in CIViC	civic
Cabozantinib + ForetinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1249 Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors r… (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC	civic